Market Overview

Benzinga's Top Initiations

Share:
Benzinga's Top Initiations
Related RPRX
Repros Therapeutics Shares Rally Following Ladenburg Upgrade To Buy, Positive Data
Benzinga's Top Upgrades
FDA Ad Comm backs expanded criteria for drug to show clinical benefit of treatments for secondary hypogonadism (Seeking Alpha)
Related
The Bull And Bear Case For Workday Following An In-Line Q3
Billing Headwinds, Deal Delays Worked Against Workday In Q3
InsiderInsights.com Daily Round Up 12/7/16: First Trust High Income Long Short Fund, Century Bancorp, American Assets Trust (Seeking Alpha)

Analysts at Lazard Capital initiated coverage on shares of Repros Therapeutics (NASDAQ: RPRX) with a “buy” rating. The target price for Repros Therapeutics is set to $26. Repros Therapeutics' shares closed at $11.83 yesterday.

Citigroup initiated coverage on shares of Workday (NYSE: WDAY) with a “neutral” rating. The target price for Workday is set to $58. Workday's shares closed at $52.61 yesterday.

Wedbush initiated coverage on shares of Denny's (NASDAQ: DENN) with an “outperform” rating. The target price for Denny's is set to $6. Denny's stock closed at $4.98 yesterday.

Analysts at Credit Suisse initiated coverage on shares of Williams-Sonoma (NYSE: WSM) with a “neutral” rating. The target price for Williams-Sonoma is set to $49. Williams-Sonoma's shares closed at $44.90 yesterday.

Latest Ratings for RPRX

DateFirmActionFromTo
Nov 2016Ladenburg ThalmannUpgradesNeutralBuy
Dec 2015Brean CapitalTerminatesBuy
Oct 2015Brean CapitalDowngradesBuyHold

View More Analyst Ratings for RPRX
View the Latest Analyst Ratings

Posted-In: Top InitiationsInitiation Analyst Ratings

 

Related Articles (DENN + RPRX)

View Comments and Join the Discussion!